Bronchial asthma – therapy

With the help of modern medicine, bronchial asthma is an easily treatable condition nowadays. Here is an overview of the most important therapeutic measures.

Medication-based therapy for bronchial asthma

The focus of all therapeutic measures for bronchial asthma is medication-based treatment. The active agents are often administered in the form of a medicated spray (metered-dose inhaler).

There are 3 groups of drugs, in particular, that allow for a relatively symptom-free life for patients:

Asthma bronchiale - Therapie
  1. Bronchospasmolytics dilate the bronchi and relieve the cramping of the bronchial musculature (bronchospasms) during an asthmatic attack.
  2. Corticosteroids are drugs containing cortisone that have an anti-inflammatory effect. Just like bronchospasmolytics, they are administered through inhalation in most cases.
  3. Secretolytics are secretion-loosening agents that dilute stubborn phlegm and ease expectoration.

Auxiliary devices for bronchial asthma


A peak flow meter is used for regular measurement of the peak flow, i.e. the maximum flow rate during exhalation, and is part of the basic equipment of chronic pulmonary patients. Based on the progression of values obtained, patients can monitor the course of their condition and identify any worsening early on.

Inhalation devices (spacers)

Spacers such as the RC-Chamber® improve and facilitate the use of metered-dose inhalers. Children and older asthma patients, in particular, often have difficulty coordinating the inhalation and the burst of spray. Studies have shown that the additional use of a spacer results in more active agent penetrating the target area.

Respiratory physiotherapy with PEP / OPEP systems

With the use of PEP / OPEP systems such as the RC-Cornet®, asthma patients can conduct easy and effective training for the airways. Exhaling into the device generates fluctuations in pressure and flow that are transmitted to the bronchial system. This process dilates the bronchi and physically eases expectoration.

RC-Chamber® spacer – Use and method of action


By loading the video, you agree to YouTube's privacy policy.
Learn more

Load video

Atemtherapiegerät RC‑Cornet® PLUS

RC-Cornet® PLUS

The PLUS for your quality of life

The new RC-Cornet® PLUS pep therapy device produces an oscillating positive exhalation pressure that loosens up sticky bronchial phlegm in the event of chronic respiratory diseases, reduces coughing and shortness of breath.


Hyposensitisation is a specific type of immunotherapy for certain forms of allergic bronchial asthma. With each allergy shot, the body receives a tiny quantity of allergen administered into the skin. Over time, the dose is increased and the body is sensitised to the allergen. With successful therapy, contact with the allergen results in only a weak or possibly no allergic reaction. The patient’s allergy remains existent, but there is no reaction.
However, not every hyposensitisation results in the desired success. With increasing age, the number of allergens mostly increases and the chances of success decrease. Treatment risks are also present because the patient is directly exposed to the allergy-triggering substance. In addition to serious local reactions (swelling, welts), asthma symptoms such as heavy coughing and shortness of breath may also appear. Therefore, hyposensitisation may only be conducted under a physician’s supervision.
Asthma emergency plan

What can be done for shortness of breath?

In case of an emergency asthmatic attack, it is best to have a safe and practised process in place!

Here, the new and patented guardian angel concept of the RC-Chamber® including the spacer in a safety pouch, a emergency plan, and guardian angel hanger, can be of help.

Subscribe to our

Tips and information on healthy airways!

  • for all who wish to breathe better
  • free of charge and convenient e-mails
  • compact newsletter once a month

For all those who deal with pneumological topics related to the respiratory tract in a professional context, please find here the subscription to the CEGLA FACHNEWSLETTER.